Aurum Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Welkom South Africa (1998)

Organization Overview

First Clinical Trial
2009
NCT01017536
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Aurum Institute | Aurum Institute for Health Research | Global CEO: The Aurum Institute, NPC | Prof Gavin John Churchyard | The Aurum Institute NPC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

HIV Infections (Phase 1)

Infections (Phase 2)

Latent Tuberculosis (Phase 2)

Respiratory Tract Infections (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 2)

Vaccinia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 39